Importantly, the best survival benefit was obtained in tumor‐bearing mice treated with the combination therapy of TMZ with RGD4C/AAVP‐Grp78‐HSVtk and GCV, as compared to TMZ or vector alone (half the animals survived 72 days versus 66 and 54, respectively). The gene discussed is HSPA5; the disease is neoplasm.